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Abstract 
 
Background/Aims: Endometriosis is a benign but chronic disorder associated with pelvic pain 
and infertility. Enhanced proliferation and reduced apoptosis susceptibility are characteristics 
of endometriosis. Cordycepin is a poly(A) polymerase (PAP) inhibitor. It produces shortening 
of poly(A) tails, leading to de-stabilization of mRNAs, and finally to proliferation inhibiton 
and cell death in normal and tumor cells. The potential of Cordycepin to block proliferation 
and survival of 11z human immortalized epithelial endometriotic cells was determined. 
Methods: 11z cell cultures were treated with Cordycepin. Cordycepin-induced inhibition of 
proliferation and alterations in protein expression and protein phosphorylation were determined 
by the MTT-assay and immunoblot analysis, respectively. 
Results: Cordycepin induced the rapid and significant upregulation of the cell cycle 
progression inhibitor p21 and the downregulation of the cell cycle progression promoter cyclin 
D1, finally leading to the inhibition of the proliferation of 11z human epithelial endometriotic 
cells. Cordycepin reduced the phosphorylation of the p38 MAPK and the retinoblastoma 
protein (pRb). It also activated caspase-dependent, intrinsic apoptosis, as documented by the 
proteolytic cleavage of the caspase-9, caspase-3, and the PARP-1 precursor. 
Conclusion: The mRNA polyadenylation inhibitor Cordycepin inhibits proliferation and 
survival of endometriotic cells. 
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Introduction 
Endometriosis is a common, benign, and chronic disorder characterized by the proliferation of 
endometrial tissue outside the uterine cavity. Endometriosis is frequently associated with 
infertility and pelvic pain in affected women. The prevalence of endometriosis reaches 10-15% 
in women in the reproductive age and incidence rates can reach 30-50% among women with 
infertility. Endometriosis is not a life-threatening disease, but it causes a substantial negative 
impact on physical, psychological and social integrity of affected women. These include well-
being, personal relationships, and desire for children. It also causes time off work and the need 
for expensive surgery and medical therapies. Diagnosis is difficult and needs an invasive 
approach. Available treatments (surgical and medical) are symptomatical rather than causative, 
because etiology and pathophysiology are still not completely understood. Endometriosis is an 
estrogen-dependent disease and standard medical treatment aims at downregulating ovarian 
function and/or antagonizing the effect of estrogen in ectopic endometrial implants using 
GnRH-Analoga, progestins, and contraceptives. Recent research has focused on inhibitors of 
angiogenesis and matrix metalloproteinases and on epigenetically acting agents [1-4]. 
 Cordycepin (3’-deoxyadenosine), the main constituent of the mycelia of Cordyceps 
militaris, has numerous biological activities, including inhibition of cell proliferation, 
activation of apoptosis, and inhibition of cell migration and invasivness [5-10]. Cordycepin has 
been shown to reduce tumor formation in mice [5] and has therefore been proposed as cancer 
drug. Cordycepin is an adenosine analogue and inhibits mRNA polyadenylation, presumably 
by causing chain termination after it has been incorporated as cordycepin-triphosphate [11]. 
Polyadenylation of mRNA, also referred to as 3’-end mRNA processing, is crucial to mRNA 
stability and to nuclear export of mRNA [12]. The stabilization of the newly transcribed 
mRNA and the translation of mRNA into a protein are crucial steps in protein synthesis in all 
cells. mRNA polyadenylation is a regulated process carried out in a multiprotein-complex, 
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wherein poly(A) polymerase (PAP) is the enzyme performing the addition of multiple 
adenosine-monophosphates (150 to 250) to the mRNA, resulting in a poly(A) tail. Cordycepin, 
lacking the 3’-OH-group normally present in adenosine, leads to the shorting of poly(A) tail 
length in a dose-dependent manner [13], confirming its PAP-inhibitor activity. PAP has been 
suggested as potential therapeutic target [14]and its enzymatic activity even as potential 
independent prognostic marker in primary breast cancer [15]. 
Because enhanced proliferation and reduced apoptosis susceptibility are characterisics 
in endometriosis, we determined the effects of Cordycepin on proliferation and apoptosis in 
11z human immortalized epithelial endometriotic cells. 
 
 
 
Materials and Methods 
Cell culture and drug 
The immortalized human epithelial endometriotic cell line (11z) employed in this study was 
provided by Dr. A. Starzinski-Powitz (Institute of Anthropology and Human Genetics, Johann-
Wolfgang-Goethe University, Frankfurt, Germany). It was generated by in situ electroporation 
of primary human peritoneal epithelial endometriotic cells with SV-40 T-antigen. The 
characteristics of this cell line have been previously described [16, 17]. 11z cells were cultured 
in DMEM medium (21980; Invitrogen, Basel, Switzerland) containing 10% FCS (Oxoid, 
Basel, Switzerland), penicilin (100 U/ml) and streptomycin (100 g/ml) at 37ºC in an 
atmosphere with 10% CO2 and 95% humidity. Cordycepin (3’-deoxyadenosine) was purchased 
(Sigma, Buchs, Switzerland) and aliquots prepared in water were stored at -20ºC. 
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Proliferation inhibition 
Proliferation inhibition of 11z cells in response to Cordycepin was assessed by the MTT-assay. 
Briefly, 30’000 cells in 200 l medium were seeded into 96-well plates. Three days after 
seeding cultures were left untreated (controls) or were treated with various concentrations of 
Cordycepin for 96h. MTT-dye (dissolved in PBS) was added to a final concentration of 500 
g/ml. After 4h, the medium was removed and the crystals were dissolved in 200 l DMSO. 
Optical density (OD, absorbance at 540 nm) was measured (SpectraFluor Plus Reader; TECAN 
AG, Hombrechtikon, Switzerland). Data are presented as the proliferation relative to untreated 
control (calculated from the respective OD values) as a function of Cordycepin concentration. 
Data points are the mean ± SD of three independent experiments performed in triplicates. 
 
Preparation of cell lysates and immunoblot analysis 
Cell lysates were produced from 11z cell cultures that were subconfluent at the time of analysis 
(avoiding undesired effects due to factors like contact inhibition). Cells were grown to 70% 
confluence, treated with various concentrations of Cordycepin for various periods of time as 
indicated, and lysed for immunoblot analysis performed following standard protocols. Protein 
concentration of cell lysates was determined by the BCA Protein Assay Kit (23227; Pierce, 
Perbio Science, Lausanne, Switzerland). Twenty g cell lysate protein was loaded and 
separated using SDS-PAGE, followed by blotting onto a polyvinylidene difluoride membrane 
(Amersham Biosciences, Otelfingen, Switzerland). Proteins were detected by the specific 
primary antibodies and the respective secondary, horseradish peroxidase-conjugated anti-
mouse (M15345; Transduction Laboratories, Lexington, KY) or horseradish peroxidase-
conjugated anti-rabbit (7074; Cell Signaling; BioConcept, Allschwil, Switzerland) antibodies. 
The primary antibodies used were: p21 (2946; Cell Signaling), cyclin D1 (2926; Cell 
Signaling), PARP-1 (9542; Cell Signaling, recognizing both the 116 kD full-length PAPR-1 
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and the cleaved 89 kD fragment), caspase-9 (9502; Cell Signaling, recognizing the 47 kD 
precursor and the 37 kD and 17 kD fragments), caspase-3 (9662; Cell Signaling, recognizing 
the 37 kD precursor and the 17 kD fragment), phospho-ERK1/2 (9106; Cell Signaling, 
recognizing ERK phosphorylated at thr202 and tyr204), ERK1/2 (9102, Cell Signaling, 
recognizing both the non-phosphorylated and the phosphorylated ERK1/2), phospho-p38 
(9211; Cell Signaling, recognizing p38 MAPK phosphorylated at thr180 and tyr182), p38 
(9212; Cell Signaling, recognizing both phosphorylated and non-phosphorylated p38 MAPK), 
and phospho-pRb (9308; Cell Signaling, recognizing Rb protein phosphorylated at ser807 and 
ser811). Mouse anti--actin (A5441; Sigma) was used as sample loading control. Complexes 
were visualized by enhanced chemiluninescence (Amersham Biosciences) and 
autoradiography. Quantitative analysis of the complexes (intensity on the autoradiograph) was 
performed by densitometry (normalized against ß-actin) using the Scion Image 4.01 Win 
software (Scion Corporation, Frederick, MD). 
 
Statistical analysis 
Mean ± SD values were calculated (where appropriate). Statistical analysis was performed 
using the two-tailed Student’s t-test. p values <0.05 are considered statistically significant. 
 
 
 
Results 
Cordycepin inhibits proliferation of 11z cells 
Endometriosis is characterized by increased proliferation of endometriotic tissue. We 
determined whether Cordycepin inhibits proliferation of 11z cells. MTT-assay data showed 
that Cordycepin significantly inhibited the proliferation of these cells in a concentration-
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dependent manner (fig. 1). Half-maximal inhibition (IC50) was reached with 490 M 
Cordycepin (96h treatment). Proliferation of 11z cells is therefore inhibited by Cordycepin. 
 
Cordycepin upregulates p21 and downregulates cyclin D1 expression and pRb 
phosphorylation 
p21 is an endogenous cell cycle progression inhibitor which is upregulated in cancer cells in 
response to cytostatic and cytotoxic agents. We determined whether Cordycepin induces 
upregulation of p21 expression in 11z cells. Immunoblot data demonstrated (fig. 2A) that 
Cordycepin produced a rapid (14h of Cordycepin treatment), concentration-dependent 
upregulation of p21, which was detectable already with 50 M Cordycepin. Cordycepin also 
produced in a time- and concentration-dependent manner a strong decrease in the levels of 
cyclin D1 (fig. 2B) and of phosphorylated (serines 807 and 811) retinoblastoma protein (pRb) 
(fig. 2C) within 48h of treatment, two positive regulators of cell cycle progression. 
Proliferation inhibition by Cordycepin is thus accompanied by upregulation of p21 and 
downregulation of  cyclin D1 expression and pRb phosphorylation. 
 
Cordycepin inhibits phosphorylation of p38 MAPK 
The extracellular signal-regulated kinase (ERK1/2) and the p38 mitogen-activated protein 
kinase (MAPK) are important signal transduction pathway protein kinases and believed to have 
also a role in endometriosis [18]. We determined the effects of Cordycepin on the 
phosphorylation of the ERK1/2 and the p38 MAPK, a characteristic of the enzymatic activity 
of these kinases in 11z cells. Immunoblot (fig. 3A) and densitometry (fig. 3B) demonstrated 
that Cordycepin produced a detectable (48h of treatment) and then substantial (72h of 
treatment) decrease of phosphorylation of p38 MAPK (threonine 180 and tyrosine 182) in a 
concentration- and time-dependent manner. A decrease in ERK1/2 phosphorylation (threonine 
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202 and tyrosine 204) was only detected after 96h with the highest (600 M) Cordycepin 
concentration. Proliferation inhibition by Cordycepin is therefore accompanied by 
downregulation of p38 MAPK signaling. 
 
Cordycepin activates caspase-dependent apoptosis 
Resistance to apoptosis is one of the characteristics of endometriosis. We determined whether 
Cordycepin, like in cancer cells [7], activates apoptosis in 11z cells. Immunoblot data (fig. 4) 
demonstrated proteolytic cleavage of the 116 kD PARP-1 precursor into a 89 kD-fragment (a 
measure for ongoing apoptosis) with 600 M Cordycepin after 48h of treatment, with 500 M 
Cordycepin after 72h of treatment, and with 400 M Cordycepin after 96h of treatment. 
Cordycepin also produced detectable decreases in the levels of the 47 kD caspase-9 and the 37 
kD caspase-3 precursors after 48h of treatment and strong decreases after 72h and 96h of 
treatment, respectively. The respective cleaved fragments were not detected. Cordycepin thus 
activates caspase-9- and caspase-3-dependent apoptosis in 11z cells. 
 
 
 
Discussion 
mRNA polyadenylation plays essential roles in mRNA stability, nuclear export, and translation 
and is an important step in many cellular processes [12]. Abrogation of mRNA 
polyadenylation through PAP inhibition has been shown to associate with anticancer activities 
[5]. PAP has therefore been proposed as therapeutical target and inhibitors mRNA 
polyadenylation as potential anticancer agents. 
Endometriosis is characterized by increased proliferation, reduced apoptosis 
susceptibility, and angiogenic and invasive potential and therefore shares common featrures 
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with cancers. We hypothesized that inhibition of mRNA polyadenylation by the PAP inhibitor 
Cordycepin negatively affects proliferation and survival in 11z epithelian endometriotic cells in 
vitro. We demonstrate that proliferation can be inhibited and apoptosis can be activated by 
Cordycepin in these cells. This study is the first to address the issue of encountering these 
cellular processes crucial to endometriosis by the inhibition of mRNA polyadenylation. We 
conclude (i) that human epithelial endometriotic cells are sensitive to mRNA polyadenylation 
inhibition and (ii) that Cordycepin might be a potential candidate for treatment of 
endometriosis. 
Increased proliferation is an important characteristic in endometriosis and regulators of 
cell cycle progression are targets for proliferation suppression. Proliferation and cell cycle 
progression are highly regulated processes involving the concerted action of cell cycle 
promotors (e.g. cyclins) and cell cycle inhibitors (e.g. p21, pRb). Cyclins complex with cyclin-
dependent kinases (CDKs) at a specific point during G1 and phosphorylate and inactivate pRb, 
allowing cell cycle progression. p21 is an stress-responsive inhibitor of cell cycle progression 
and thus a crucial factor in the inhibition of proliferation. p21 interacts and forms 
hererodimeric complexes with cyclin-dependent kinases with cyclins, promotors of cell cycle 
progression and proliferation [19]. As an inhibitor of CDKs, p21 prevents phosphorylation of 
pRb, thereby repressing the transcription of genes required for the G1-S transition of the cell 
cycle and thus inhibiting proliferation [20-22]. Hypophosphorylated pRb acts as a tumor 
suppressor that may have a role in endometriosis [23]. Our results show that Cordycepin 
upregulates p21 expression and downregulates expression of cyclin D1 and phosphorylation of 
pRb, suggesting that these events contribute to the proliferation inhibition of epithelial 
endometriotic cells. 
The dysregulation of apoptosis and in particular apoptosis resistance are other 
characteristics of endometriosis [24]. Apoptosis (also referred to as programmed cell death) is 
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important in the control of cell homeostasis in many organisms and is a crucial process in 
response to cellular stress [25, 26]. Our finding that Cordycepin produced the fragmentation of 
the PARP-1 precursor into its fragments, an event typical for ongoing apoptosis, clearly 
demonstrates that 11z epithelial endometriotic cells undergo apoptosis after a 48h treatment 
with 600 M Cordycepin, after a 72h treatment with 500 M Cordycepin or after a 96h 
treatment with 400 M Cordycepin. This Cordycepin-induced apoptosis was caspase-
dependent, as manifested by the reduction in the levels of the caspase-9 and caspase-3 
precursors. Caspases are a family of proteases that are one of the main executors of the 
apoptotic process. They exist as inactive zymogens and are cleaved to form active enzymes 
following the induction of apoptosis. The involvement of the caspase-9 indicates that 
Cordycepin activated the intrinsic apoptotic pathway in these cells, in line with a previous 
study with mouse leydig tumor cells [27]. Caspase-9 is the initiator caspase of the intrinsic 
apoptotic pathway. It is activated upon release of cytochrome c from the mitochondria and can 
activate effector caspases such as caspase-3. This leads to cleavage of key cellular proteins 
(e.g. PARP-1, cytoskeletal proteins) to drive forward the biochemical events that culminate in 
death and the dismantling of the cell. 
Endometriosis is an estrogen-dependent disease and also depends on multiple growth 
factors and cytokines [28]. These extracellular growth stimuli are transduced via multiple 
signaling pathways to intracellular targets that, in turn, control proliferation, growth, and 
survival. The ERK1/2- and the p38 MAPK-signaling pathways respond to a wide range of 
stimuli, including stress [29], and transduce extracellular growth stimuli to intracellular targets 
that, in turn, control proliferation, growth, and survival. Estrogen promotes phosphorylation 
and activation of ERK1/2 and p38 in endometriotic cells [30, 31] and an inhibitor of p38 
suppresses the development of endometriosis in a murine model [18], suggesting that these 
pathways have a role in endometriosis. We show that Cordycepin abrogated p38 
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phosphorylation in a time- and concentration-dependent manner in epithelial endometriotic 
cells, suggesting that Cordycepin downregulates p38-signaling. This reduction, like that of 
cyclin D1 expression and that of pRb phosphorylation, occurred at non-apoptotic 
concentrations and thus was not a consequence of apoptosis. However, ERK1/2 signaling was 
not affected by Cordycepin; the reduction of ERK1/2 phosphorylation detected after a 96h 
treatment with 600 M Cordycepin is likely a consequence of apoptosis rather than an effect of 
Cordycepin itself. 
The present study demonstrates that Cordycepin suppresses proliferation and survival 
of epithelial endometriotic cells. Increased proliferation and reduced apoptosis are hallmarks of 
endometriosis, and Cordycepin may therefore be a potential candidate to therapeutically 
encounter endometriosis. This is the first study addressing the issue of endometriosis and 
mRNA polyadenylation, but the intervention at the mRNA processing level presents a novel 
approach to target endometriotic cells. This may open up research into a potential alternative to 
current treatment options against endometriosis. Of course, further studies are needed to addess 
the issues of cell-specificity of Cordycepin (endometriotic cells versus normal cells) and of 
how to administer Cordycepin in endometriosis patients. A possibility may be Cordycepin-
encapsulating liposomes, in analogy to ATP-loaded liposomes for treatment of myocardial 
ischemia [32]. 
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FIGURE LEGENDS 
Fig. 1. Cordycepin-induced proliferation inhibition of 11z human epithelial endometriotic 
cells. Cells were incubated in absence (control) or presence of Cordycepin (250 M, 500 M, 
1000 M, 2500 M) for 96h. MTT-assay data are presented as the relative proliferation 
(expressed as the percentage of untreated control calculated from the respective OD values) as 
a function of Cordycepin concentration. Data points are the mean ± SD of three independent 
experiments performed in triplicates. *p<0.05; **p<0.005. 
 
Fig. 2. Cordycepin-induced induction of p21 protein expression (A) and downregulation of 
cyclin D1 (B) and phosphorylation of pRb at serines 807 and 811 (C) in 11z human epithelial 
endometriotic cells. Cells were incubated without (control) or with different concentrations of 
Cordycepin for the periods of time indicated and lysed. Proteins were separated by PAGE and 
blotted. The respective complexes were detected by chemiluminescence and autoradiography. 
-Actin was the sample loading control (representative of two independent data sets). 
 
Fig. 3. (A) Effects of Cordycepin on the phosphorylation of p38 MAPK (threonine 180 and 
tyrosine 182) and ERK1/2 (threonine 202 and tyrosine 204) assessed by immunoblot analysis. 
Cells were incubated in absence (control) or in presence of various concentrations of 
Cordycepin for different periods of time as indicated. Then cells were lysed, proteins were 
separated by PAGE analysis and blotted, and the respective complexes were detected by 
chemiluminescence and autoradiography. -Actin was the sample loading control 
(representative of two independent data sets). (B) A quantitative (based on densitometric 
analysis) presentation of the Cordycepin-induced changes in phosphorylation of p38 MAPK is 
given in the bar diagram. The respective data are presented as the relative amount of 
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phosphorylated p38 to the total amount (phosphorylated and non-phosphorylated) of p38 as a 
function of Cordycepin concentration and time of treatment. 
 
Fig. 4. Cordycepin-induced apoptosis in 11z human epithelial endometriotic cells, presented as 
the cleavage of the full-length 116 kD PARP-1 precursor into its 89 kD fragment and as the 
decrease in the levels of the 47 kD caspase-9 and the 37 kD caspase-3 precursors (the 
respective cleaved fragments were not detected). Cells were incubated in absence (control) or 
in presence of various concentrations of Cordycepin for different periods of time as indicated. 
Cells were lysed, proteins were separated by PAGE analysis and blotted, and the respective 
complexes were detected by chemiluminescence and autoradiography. -Actin was the sample 
loading control (representative of two independent data sets). 
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